Benzinga | Feb 8, 2021 05:06PM EST

Recap: Enanta Pharmaceuticals Q1 Earnings

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 163.08% year over year to ($0.41), which beat the estimate of ($0.74).

Revenue of $31,743,000 declined by 39.62% from the same period last year, which beat the estimate of $28,790,000.

Outlook

Enanta Pharmaceuticals hasn't issued any earnings guidance for the time being.

Enanta Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Feb 08, 2021

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.enanta.com%2F&eventid=2947516&sessionid=1&key=9E656BA22915EB0B1659FBCED981AF9B&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $58.59

52-week low: $38.40

Price action over last quarter: Up 28.12%

Company Overview

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.